• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫基因组分析在肾癌患者预后预测模型中的应用。

Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer.

机构信息

Department of Urology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

Department of Urology, Beijing Huairou Hospital, Beijing, China.

出版信息

Front Immunol. 2021 Oct 12;12:762120. doi: 10.3389/fimmu.2021.762120. eCollection 2021.

DOI:10.3389/fimmu.2021.762120
PMID:34712244
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8546215/
Abstract

BACKGROUND

Renal cell carcinoma (RCC) is associated with poor prognostic outcomes. The current stratifying system does not predict prognostic outcomes and therapeutic benefits precisely for RCC patients. Here, we aim to construct an immune prognostic predictive model to assist clinician to predict RCC prognosis.

METHODS

Herein, an immune prognostic signature was developed, and its predictive ability was confirmed in the kidney renal clear cell carcinoma (KIRC) cohorts based on The Cancer Genome Atlas (TCGA) dataset. Several immunogenomic analyses were conducted to investigate the correlations between immune risk scores and immune cell infiltrations, immune checkpoints, cancer genotypes, tumor mutational burden, and responses to chemotherapy and immunotherapy.

RESULTS

The immune prognostic signature contained 14 immune-associated genes and was found to be an independent prognostic factor for KIRC. Furthermore, the immune risk score was established as a novel marker for predicting the overall survival outcomes for RCC. The risk score was correlated with some significant immunophenotypic factors, including T cell infiltration, antitumor immunity, antitumor response, oncogenic pathways, and immunotherapeutic and chemotherapeutic response.

CONCLUSIONS

The immune prognostic, predictive model can be effectively and efficiently used in the prediction of survival outcomes and immunotherapeutic responses of RCC patients.

摘要

背景

肾细胞癌（RCC）与不良预后相关。目前的分层系统不能准确预测 RCC 患者的预后结果和治疗获益。在这里，我们旨在构建一个免疫预后预测模型，以帮助临床医生预测 RCC 的预后。

方法

本研究中，我们开发了一个免疫预后特征，并基于癌症基因组图谱（TCGA）数据集在肾透明细胞癌（KIRC）队列中验证了其预测能力。进行了几项免疫基因组学分析，以研究免疫风险评分与免疫细胞浸润、免疫检查点、癌症基因型、肿瘤突变负担以及对化疗和免疫治疗的反应之间的相关性。

结果

免疫预后特征包含 14 个与免疫相关的基因，被发现是 KIRC 的独立预后因素。此外，免疫风险评分被确定为预测 RCC 总体生存结果的新型标志物。风险评分与一些重要的免疫表型因素相关，包括 T 细胞浸润、抗肿瘤免疫、抗肿瘤反应、致癌途径以及免疫治疗和化疗反应。

结论

免疫预后、预测模型可有效地用于预测 RCC 患者的生存结果和免疫治疗反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/6a0486315d3a/fimmu-12-762120-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/2b41fd106910/fimmu-12-762120-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/b3e77888864b/fimmu-12-762120-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/93c1385ee488/fimmu-12-762120-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/9ba1df15f17a/fimmu-12-762120-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/3924aa14e671/fimmu-12-762120-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/a839ee7e87f2/fimmu-12-762120-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/4af1669fe767/fimmu-12-762120-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/b8d9d5d3d676/fimmu-12-762120-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/24a855027eef/fimmu-12-762120-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/b8b693af13fd/fimmu-12-762120-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/a63d3534ef75/fimmu-12-762120-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/0f41fb2ee2b4/fimmu-12-762120-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/6a0486315d3a/fimmu-12-762120-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/2b41fd106910/fimmu-12-762120-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/b3e77888864b/fimmu-12-762120-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/93c1385ee488/fimmu-12-762120-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/9ba1df15f17a/fimmu-12-762120-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/3924aa14e671/fimmu-12-762120-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/a839ee7e87f2/fimmu-12-762120-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/4af1669fe767/fimmu-12-762120-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/b8d9d5d3d676/fimmu-12-762120-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/24a855027eef/fimmu-12-762120-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/b8b693af13fd/fimmu-12-762120-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/a63d3534ef75/fimmu-12-762120-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/0f41fb2ee2b4/fimmu-12-762120-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3891/8546215/6a0486315d3a/fimmu-12-762120-g013.jpg

相似文献

1
Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer.免疫基因组分析在肾癌患者预后预测模型中的应用。
Front Immunol. 2021 Oct 12;12:762120. doi: 10.3389/fimmu.2021.762120. eCollection 2021.
2
A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma.一种新型基于九 miRNA 的模型，用于改善肾细胞癌的预后预测。
BMC Cancer. 2022 Mar 12;22(1):264. doi: 10.1186/s12885-022-09322-9.
3
The JAK-STAT signaling-related signature serves as a prognostic and predictive biomarker for renal cell carcinoma immunotherapy.JAK-STAT 信号相关特征可作为肾细胞癌免疫治疗的预后和预测生物标志物。
Gene. 2024 Nov 15;927:148719. doi: 10.1016/j.gene.2024.148719. Epub 2024 Jun 23.
4
A novel prognostic predictor of immune microenvironment and therapeutic response in clear cell renal cell carcinoma based on angiogenesis-immune-related gene signature.基于血管生成-免疫相关基因特征的透明细胞肾细胞癌免疫微环境和治疗反应的新型预后预测指标
Heliyon. 2023 Dec 10;10(1):e23503. doi: 10.1016/j.heliyon.2023.e23503. eCollection 2024 Jan 15.
5
Integrative bioinformatics analysis of a prognostic index and immunotherapeutic targets in renal cell carcinoma.整合生物信息学分析在肾细胞癌中的预后指标和免疫治疗靶点。
Int Immunopharmacol. 2020 Oct;87:106832. doi: 10.1016/j.intimp.2020.106832. Epub 2020 Jul 29.
6
Construction of exosome-related genes risk model in kidney cell carcinoma predicts prognosis and immune therapy response.构建肾癌中外泌体相关基因风险模型可预测预后和免疫治疗反应。
Aging (Albany NY). 2024 May 7;16(9):7622-7646. doi: 10.18632/aging.205767.
7
A promising Prognostic risk model for advanced renal cell carcinoma (RCC) with immune-related genes.具有免疫相关基因的晚期肾细胞癌（RCC）的有前途的预后风险模型。
BMC Cancer. 2022 Jun 23;22(1):691. doi: 10.1186/s12885-022-09755-2.
8
Construction and validation of an autophagy-related long noncoding RNA signature for prognosis prediction in kidney renal clear cell carcinoma patients.构建并验证自噬相关长非编码 RNA 标志物用于预测肾透明细胞癌患者的预后
Cancer Med. 2021 Apr;10(7):2359-2369. doi: 10.1002/cam4.3820. Epub 2021 Mar 2.
9
Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.与透明细胞肾细胞癌患者肥胖悖论相关的转录组特征：一项队列研究。
Lancet Oncol. 2020 Feb;21(2):283-293. doi: 10.1016/S1470-2045(19)30797-1. Epub 2019 Dec 20.
10
Identification of immunogenic cell death-related signature on prognosis and immunotherapy in kidney renal clear cell carcinoma.鉴定肾透明细胞癌预后和免疫治疗相关的免疫原性细胞死亡特征。
Front Immunol. 2023 Aug 18;14:1207061. doi: 10.3389/fimmu.2023.1207061. eCollection 2023.

引用本文的文献

1
Exploring the role of key gene PTTG1 in clear cell renal carcinoma based on bioinformatics analysis and In-vitro cell experiments.基于生物信息学分析和体外细胞实验探索关键基因PTTG1在肾透明细胞癌中的作用
Toxicol Res (Camb). 2025 Jun 17;14(3):tfaf078. doi: 10.1093/toxres/tfaf078. eCollection 2025 Jun.
2
A novel glycogene-related signature for prognostic prediction and immune microenvironment assessment in kidney renal clear cell carcinoma.一种用于肾透明细胞癌预后预测和免疫微环境评估的新型糖原相关特征。
Ann Med. 2025 Dec;57(1):2495762. doi: 10.1080/07853890.2025.2495762. Epub 2025 May 7.
3
Uncovering the heterogeneity of NK cells on the prognosis of HCC by integrating bulk and single-cell RNA-seq data.

本文引用的文献

1
Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma.关于胶质瘤预后、基因组改变和免疫格局的新型突变特征分类系统的综合分子分析
Front Mol Biosci. 2021 Jul 7;8:682084. doi: 10.3389/fmolb.2021.682084. eCollection 2021.
2
Association of Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma.食管腺癌患者中突变与肿瘤突变负荷、预后及抗肿瘤免疫的关联
Front Genet. 2021 May 17;12:669694. doi: 10.3389/fgene.2021.669694. eCollection 2021.
3
The Identification and Validation of Two Heterogenous Subtypes and a Risk Signature Based on Ferroptosis in Hepatocellular Carcinoma.
通过整合批量和单细胞RNA测序数据揭示自然杀伤细胞异质性对肝癌预后的影响
Front Oncol. 2025 Mar 18;15:1570647. doi: 10.3389/fonc.2025.1570647. eCollection 2025.
4
Development and validation of a prognostic model based on m6A-related lncRNAs to predict prognosis for papillary renal cell cancer patients.基于m6A相关长链非编码RNA的预测模型的开发与验证，用于预测乳头状肾细胞癌患者的预后。
Sci Rep. 2024 Dec 28;14(1):31460. doi: 10.1038/s41598-024-83263-0.
5
HOTAIR in cancer: diagnostic, prognostic, and therapeutic perspectives.癌症中的HOTAIR：诊断、预后及治疗前景
Cancer Cell Int. 2024 Dec 19;24(1):415. doi: 10.1186/s12935-024-03612-x.
6
Renal cell carcinoma and macrophage research: A bibliometric analysis (2004-2023).肾细胞癌与巨噬细胞研究：文献计量分析（2004 - 2023年）
Medicine (Baltimore). 2024 Dec 13;103(50):e40954. doi: 10.1097/MD.0000000000040954.
7
Transcriptome analysis revealed a novel nine-gene prognostic risk score of clear cell renal cell carcinoma.转录组分析揭示了透明细胞肾细胞癌的一个新的九基因预后风险评分。
Medicine (Baltimore). 2024 Sep 27;103(39):e39678. doi: 10.1097/MD.0000000000039678.
8
Poria acid inhibit the growth and metastasis of renal cell carcinoma by inhibiting the PI3K/akt/NF-κb signaling pathway.茯苓酸通过抑制PI3K/akt/NF-κb信号通路抑制肾细胞癌的生长和转移。
Heliyon. 2024 May 11;10(10):e31106. doi: 10.1016/j.heliyon.2024.e31106. eCollection 2024 May 30.
9
Construction of a hepatocytes-related and protein kinase-related gene signature in HCC based on ScRNA-Seq analysis and machine learning algorithm.基于单细胞 RNA-Seq 分析和机器学习算法构建 HCC 中与肝细胞和蛋白激酶相关的基因特征。
J Physiol Biochem. 2023 Nov;79(4):771-785. doi: 10.1007/s13105-023-00973-1. Epub 2023 Jul 17.
10
Development and validation of a novel immunotype for prediction of overall survival in patients with clear cell renal cell carcinoma.一种用于预测透明细胞肾细胞癌患者总生存期的新型免疫分型的开发与验证
Front Oncol. 2022 Sep 28;12:924072. doi: 10.3389/fonc.2022.924072. eCollection 2022.
基于铁死亡的肝细胞癌两种异质性亚型及风险特征的鉴定与验证
Front Oncol. 2021 Mar 2;11:619242. doi: 10.3389/fonc.2021.619242. eCollection 2021.
4
TTN/OBSCN 'Double-Hit' predicts favourable prognosis, 'immune-hot' subtype and potentially better immunotherapeutic efficacy in colorectal cancer.TTN/OBSCN“双打击”预测结直肠癌预后良好、“免疫热”亚型，且可能具有更好的免疫治疗疗效。
J Cell Mol Med. 2021 Apr;25(7):3239-3251. doi: 10.1111/jcmm.16393. Epub 2021 Feb 23.
5
Hypoxia Molecular Characterization in Hepatocellular Carcinoma Identifies One Risk Signature and Two Nomograms for Clinical Management.肝细胞癌中的缺氧分子特征鉴定出一种风险特征和两种用于临床管理的列线图。
J Oncol. 2021 Jan 20;2021:6664386. doi: 10.1155/2021/6664386. eCollection 2021.
6
Cancer Statistics, 2021.癌症统计数据，2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
7
A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma.一种新的免疫分类揭示了不同的免疫逃逸机制和基因组改变：对肝细胞癌免疫治疗的意义。
J Transl Med. 2021 Jan 6;19(1):5. doi: 10.1186/s12967-020-02697-y.
8
Influence of gene expression on survival of clear cell renal cell carcinoma.基因表达对肾透明细胞癌患者生存的影响。
Cancer Med. 2020 Nov;9(22):8662-8675. doi: 10.1002/cam4.3475. Epub 2020 Sep 28.
9
The impact of TNFSF14 on prognosis and immune microenvironment in clear cell renal cell carcinoma.TNFSF14 对透明细胞肾细胞癌预后和免疫微环境的影响。
Genes Genomics. 2020 Sep;42(9):1055-1066. doi: 10.1007/s13258-020-00974-0. Epub 2020 Jul 28.
10
ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy.免疫细胞人工智能（ImmuCellAI）：一种用于全面预测T细胞亚群丰度的独特方法及其在癌症免疫治疗中的应用。
Adv Sci (Weinh). 2020 Feb 11;7(7):1902880. doi: 10.1002/advs.201902880. eCollection 2020 Apr.